Naperville, IL -- (SBWIRE) -- 12/02/2013 -- Reportstack, provider of premium market research reports announces the addition of Hepatitis C Virus - Brazil Drug Forecast and Market Analysis to 2022 market report to its offering
The publisher has released its new Country report, “HCV - Brazil Drug Forecast and Market Analysis to 2022”. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck’s Victrelis (boceprevir) or Vertex’s Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. The publisher expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care.
The anticipated drivers of growth of the HCV market in Brazil include increasing awareness of the disease, the adoption of non-invasive liver diagnostic tests, and the launch of next-generation HCV therapies.
Roche’s Pegasys (peginterferon alfa-2a) is the current market leader in Brazil. Pegasys was launched in Brazil after Merck’s PegIntron (peginterferon alfa-2b), but The publisher believes that Pegasys was able to quickly dominate the market due to a perceived better side effect profile and efficacy. Sales of both Pegasys and PegIntron are projected to increase in Brazil as a result an increase in the country’s HCV treatment rate. Sales of both drugs are also expected to be boosted by their drug’s inclusion in triple therapies (i.e., DAA, peginterferon, and ribavirin).
Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Brazil from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting Brazil HCV market.
Reasons To Buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for HCV
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012-2022 in Brazil
To view the table of contents for this market research report please visit